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Abstract. Patient data from eight clinical trials were pooled and analyzed to study the efficacy and safety of the
six-dose versus four-dose regimen of artemether-lumefantrine (coartemether; Coartem) in children weighing 5–25 kg. A
total of 544 patients with uncomplicated P. falciparum malaria (six-dose: 343; four-dose: 201), matched for demographic
and baseline characteristics and individual coartemether doses were included in the analysis. Analysis of day 28 cure rate
based on the intention-to-treat and evaluable populations yielded corrected cure rates for the six-dose regimen of 93%
and 96% compared with 61% and 76%, respectively, for the four-dose regimen (P < 0.0001 for both comparisons).
Similarly high cure rates were achieved with the six-dose regimen in non-immune infants weighing as little as 5 kg. The
six- and four-dose regimens were equally well tolerated. The main finding of this analysis is that the six-dose regimen
of coartemether is safe and more efficacious than the four-dose regimen in children.
INTRODUCTION
There is a steady increase of drug-resistant P. falciparum
malaria across many tropical areas.1 Malaria is estimated to
cause about 1 million deaths/yr or 3,000 deaths/day, and most
of these deaths occur in African children.2,3 In response to the
anti-malarial drug resistance situation, the World Health Or-
ganization (WHO) recommends that treatment policies for
falciparum malaria in all countries experiencing resistance to
monotherapies should be combination therapies, preferably
those containing an artemisinin derivative.4 It has been sug-
gested that the widespread use of artemisinin-based combi-
nation therapies (ACT) could have a major impact on ma-
laria.5 In fact, in areas of relatively low malaria transmission
in Southeast Asia and South Africa, the widespread use of
ACT has reduced the burden of malaria significantly.6 Al-
though this benefit might be less marked in areas of very high
transmission in Africa, it has been recently pointed out that
ACT has the potential to be one of the greatest public health
interventions for Africa this decade.7
Artemether-lumefantrine (coartemether; Coartem) (No-
vartis Pharma AG, Basel, Switzerland) is currently the only
fixed-combination ACT widely available. Each tablet consists
of 20 mg artemether and 120 mg lumefantrine. The rationale
for this combination is that artemether rapidly reduces para-
site biomass, and the long-acting lumefantrine eliminates re-
sidual parasites. Accumulating data suggest that, for optimum
efficacy, coartemether should be given as six doses and with
food containing fat.8 Although the four-dose regimen seemed
sufficient to provide good cure rates in regions where patients
were semi-immune and in areas without multidrug resis-
tance,9 WHO expressed the desire to have a single global
dosing regimen for coartemether to avoid confusion and to
assure its long-term effectiveness. However, the safety and
tolerability of the higher dose regimen is an obvious concern
in using the six-dose regimen as the global standard. Clinical
studies investigating the six-dose regimen of coartemether
showed high day 28 parasitological cure rates and good tol-
erability in adults and children from multi-drug–resistant ar-
eas of Southeast Asia and Africa.10–14 Moreover, a high ad-
herence to the six-dose regimen was observed, with day 28
cure rates close to 100%, irrespective of whether given under
supervision or under unsupervised conditions of routine clinic
practice in Africa.13,15 In a head-to-head study performed in
Thailand, the six-dose administration schedule of coarte-
mether was more efficacious and equally well tolerated than
the four-dose regimen.10 A recently performed pooled analy-
sis of data from randomized clinical trials confirmed the su-
perior efficacy of the six-dose over the four-dose regimen in
adolescents and adults, without altering tolerability and safety
(E.A. Mueller and others, unpublished data).
Similar reassuring comparative data from children are lack-
ing. In a multicenter non-comparative study in Kenya, Nige-
ria, and Tanzania, 310 children were treated with the six-dose
regimen of coartemether. The drug was well tolerated, and
the cure rate corrected by polymerase chain reaction (PCR)
at day 28 was approximately 94%.14 The study had no com-
parative four-dose regimen arm, for ethical reasons. It was
considered that the four-dose regimen might not be suffi-
ciently efficacious in nonimmune patients likely to be en-
rolled in that study. Against this background, we performed
additional analyses on data assessed in children. Individual
patient data from clinical trials performed under the auspices
of coartemether’s manufacturer in pediatric patients weighing
between 5 and 25 kg were pooled to facilitate comparisons
between the four-dose and six-dose regimens.
The aim of this pooled analysis was to confirm that the
six-dose regimen of coartemether is more efficacious than
* Address correspondence to Edgar A. Mueller, Institute for Clinical
Pharmacology, Public Health Research Association Saxony, Medical
Faculty, Technical University, Fiedlerstrasse 27, D-01307 Dresden,
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the four-dose regimen in pediatric patients, while remaining
equally safe and well tolerated. The results of the analysis
were used for supporting the registration of the six-dose regi-
men as a single global dosing regimen, irrespective of age,
body weight, immunologic status, and anti-malarial multi-
drug resistance.
MATERIALS AND METHODS
Trial identification and patient selection. Trials were con-
sidered eligible if they included children receiving the four- or
six-dose regimen of coartemether for treatment of acute, un-
complicated P. falciparum malaria. All studies selected were
performed under the auspices of the manufacturer of coarte-
mether with similar endpoints, assessment schedule, and da-
tabase structure. Eight studies were identified and provided
individual patient data to be included in the pooled analysis
(Table 1).
Some of the selected studies included adults and children or
used a different dose regimen for certain weight groups (one
half of the standard dose per administration). Also, the per-
mitted range of baseline parasitemia varied between studies.
These differences could have confounded comparisons be-
tween six-dose and four-dose regimens. To eliminate this con-
founding factor, only patients who met the following criteria
were considered for pooling: 1) age  12 years; 2) body
weight 5–25 kg; 3) baseline parasitemia 1,000–100,000/L; 4)
same individual dose of coartemether, according to body
weight group allocation. These criteria were selected in a way
to match the characteristics of the patients included in Study
2403, which was the pivotal study to gain regulatory approval
for using the six-dose regimen in kids. It was designed in
partnership with the WHO.
All studies screened were conducted according to the Dec-
laration of Helsinki with all its amendments. Informed con-
sent was obtained from parents or legal guardians, with an
appropriate institutional review board having approved the
studies.
Study site, study design, and population. In the four-dose
regimen group, there was a comparable distribution between
African and Asian patients selected for pooling. Study 2403
was the primary source of data for the six-dose regimen and
provided the vast majority of patients on this regimen. Studies
008, 025, and 026 included both adults and children. Although
most studies were of open-label nature, the six-dose regimen
group included a lower proportion of patients from double-
blind studies than the four-dose group (6% versus 29%).
Comparators included sulfadoxine/pyrimethamine (SP, Study
010), chloroquine (Study 011), quinine (Study 003), and the
combination of mefloquine and artesunate (MAS, Studies 008
and 026). In one case (Study 025), both coartemether regi-
mens were compared within a study, in which two different
six-dose regimens were used (same total dose), with doses
given over 3 or 5 days; both six-dose regimens were consid-
ered for pooling. Studies 009 and 011 used a pediatric tablet
formulation of coartemether (one half the dose of a standard
tablet) that was produced during the original development
program but is no longer available. To maintain comparabil-
ity between dose regimens, only patients who received indi-
vidual coartemether doses equivalent to the marketed formu-
lation (i.e., two or four pediatric tablets per dose depending
on body weight) were considered for pooling.
Before enrollment into the studies, male and female pa-
tients presenting with symptoms suggestive of malaria were
assessed to be suffering from acute, uncomplicated P. falci-
parum malaria, and the diagnosis was confirmed by a positive
blood smear. Patients with signs and symptoms of severe or
complicated malaria were excluded.
In most of the trials, study endpoints included parasitologi-
cal cure rate on days 7, 14, and 28. Cure rates were not evalu-
ated at day 28 in Studies 010 and 011. In Studies 003, 009, 025,
026, and 2403, PCR genotyping of paired blood samples was
used to account for reinfections. Secondary outcomes in-
cluded parasite clearance time (PCT), fever clearance time
(FCT), and gametocyte carriage. Safety assessments consisted
of monitoring and recording of all adverse events (AEs) and
serious adverse events (SAEs), physical examinations, regular
monitoring of hematology and blood chemistry, and regular
recordings of electrocardiograms (ECGs) and vital signs. Two
formulae (Fridericia and Bazett) were used to calculate the
heart rate–adjusted QT interval (QTc).
Drug regimens. Table 2 summarizes the drug regimen of
coartemether by body weight used in the trials that provided
patients for pooling. Each standard tablet of coartemether
contained 20 mg of artemether and 120 mg of lumefantrine,
whereas the pediatric tablet formulation contained only 10
mg of artemether and 60 mg of lumefantrine. For reasons
outlined above, patients taking one or three pediatric tablets
were excluded from pooling. Patients on the four-dose regi-
men received their doses at 0, 6–8, 24, and 48 hours, whereas
TABLE 1
Summary of studies providing individual patient data for pooled analysis
Study no. Region/year/study design Enrolled patients
Patients (n) coartemether
Overall* Qualified for pooling
4-dose 6-dose 4-dose 6-dose
[009]16 Gambia/1995–96/OL 60 60 0 7 0
[010]17 Gambia/1996–97/DB,MC 287 144 0 48 0
[011]18 Tanzania/1996/OL 260 130 0 52 0
[003] Thailand/1995–96/OL,MC 219 79 0 55 0
[008]19 Thailand/1995–96/OL 617 49 0 29 0
[025]10 Thailand/1996–97/DB,MC 359 11 26 10 19
[026]11 Thailand/1997–98/OL,MC 200 0 19 0 17
[2403]14 Kenya, Nigeria, Tanzania/2002–03/OL,MC 310 0 310 0 307
Total 2312 473 355 201 343
* All pediatric patients with 5- to 25-kg body weight and treated with coartemether.
DB, double-blind; MC, multicenter; OL, open-label.
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patients on the six-dose regimen received coartemether at 0
and 8 hours, and then twice daily on each of the following 2
days. In one treatment arm of Study 025, the six doses were
administered over 5 days. Patients were advised to take coar-
temether with fat-containing food, if tolerated.
Data analysis. Efficacy parameters were defined as follows
for the pooled analysis.
Day 7 cure rate. Proportion of patients with clearance of
asexual parasitemia within 7 days of initiation of trial treat-
ment, without subsequent recrudescence within these 7 days.
Day 14 cure rate. Proportion of patients with clearance of
asexual parasitemia within 7 days of initiation of trial medi-
cation, without subsequent recrudescence within 14 days after
study start.
Day 28 cure rate. The 28-day cure rate was considered to
be of greatest importance, defined as the proportion of pa-
tients with clearance of asexual parasitemia within 7 days of
initiation of trial drug, without subsequent recrudescence
within 28 days after study start. Recrudescence was defined as
the existence of positive blood smears after initial clearance
of parasites from the peripheral blood. When available, re-
sults from PCR analysis were used to distinguish between
recrudescence and reinfection.
Parasite clearance time. Time from first dose until first total
and continued disappearance of asexual parasite forms that
remained for at least a further 48 hours.
Fever clearance time. Time from first dose until the first
time the body temperature decreased below and remained
less than 37.5°C for at least a further 48 hours.
Gametocyte carriage. Proportions of patients with gameto-
cytes at a given time point.
Subgroup analyses for efficacy were performed for patients
5 to < 10, 10 to < 15, and 15 to  25 kg. Safety was analyzed
in terms of AEs, SAEs, clinical laboratory evaluations, and
ECGs. AEs were defined as events that occurred after base-
line but before recurrence of malaria.
Statistical analysis. All efficacy parameters were analyzed
for the intent-to-treat (ITT) population, which was defined as
all treated patients who met the pooling criteria and had con-
firmed malaria (i.e., baseline parasite count  0). Of note, all
patients who discontinued the study before evaluation of cure
rate (day 7, 14, or 28) for any reason (including losses to
follow-up) were considered a treatment failure in the ITT
analysis for cure rates (i.e., conservative approach). Cure
rates were also analyzed for the evaluable population (i.e., all
patients in the ITT population who had parasite counts re-
corded up to the day of evaluation for cure rate: day 7, 14, or
28; if completed 7, 14, or 28 days) and took no other anti-
malarial drugs effective on P. falciparum or discontinued be-
fore day 7, 14, or 28, as relevant, because of “unsatisfactory
therapeutic effect” because of recurrence of P. falciparum.
Safety was analyzed for the safety population, defined as all
patients who received at least one dose of study medication.
For parasitological cure rates and gametocyte counts, a
treatment comparison between the four- and six-dose regi-
men of coartemether was performed using the Fisher exact
test, two-sided (P 0.05). Both, PCT and FCT were analyzed
by survival analysis methods (Kaplan-Meier estimators with
appropriate censoring and corresponding 95% confidence in-
tervals [CIs] for median event times). Otherwise, all data
analyses were done using summary descriptive statistics.
RESULTS
Size of analysis populations. A total of 544 pediatric pa-
tients were included in the pooled analysis. Table 3 shows the
numbers of patients in each defined analysis population. The
5- to < 10-kg body weight group treated with the four-dose
regimen was small because of the exclusion from this popu-
lation of patients who received doses of one pediatric tablet.
Patient disposition and baseline characteristics. The major-
ity of patients completed the studies as planned, although the
discontinuation rate was lower for the six-dose regimen than
the four-dose regimen of coartemether (Table 4); the differ-
ence mainly was in the proportion of patients discontinuing
because of unsatisfactory therapeutic effect (0.6% versus
13.4%) and who were lost to follow-up (2.0% versus 11.9%).
The latter may have been related to better study monitoring
and conduct in more recent studies (with the six-dose regi-
men) than in earlier trials (with the four-dose regimen).
There was no difference in the rates of discontinuation caused
by AEs, which were low for both regimens (six-dose: one
patient [0.3%]; four-dose: two patients [1.0%]). One patient
on the six-dose regimen died, which was unrelated to treat-
TABLE 2
Dose regimens of coartemether used by study
Weight group Dose
Study no.
009 011 010 003 008 025* 026 2403
5–10 kg Four doses of one pediatric tablet  
10–15 kg Four doses of two pediatric tablets  
15–20 kg Four doses of three pediatric tablets  
20–25 kg Four doses of four pediatric tablets  
< 15 kg Four doses of one standard tablet  
15–25 kg Four doses of two standard tablets  
5 to < 10 kg Six doses of one standard tablet 
10 to < 15 kg Six doses of one standard tablet 
15 to  25 kg Six doses of two standard tablets 
10–20 kg Four doses of one standard tablet  
21–25 kg Four doses of two standard tablets  
< 15 kg Six doses of one standard tablet  
15–25 kg Six doses of two standard tablets  
Pediatric tablet: 10 mg artemether, 60 mg lumefantrine.
Standard tablet: 20 mg artemether, 120 mg of lumefantrine.
* In study 025, two different six-dose regimens were used, with doses given over 3 or 5 days.
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ment (severe gastroenteritis contracted at home 5 days after
the end of study treatment).
Overall, demographic and malaria-related characteristics at
baseline were similar for the two coartemether groups (Table
4). Patients treated with the six-dose regimen tended to be
younger and of lower body weight than those treated with the
four-dose regimen. This reflected two factors: first, the exclu-
sion of most patients in the 5- to < 10-kg body weight group
for the four-dose regimen because they received doses of one
pediatric tablet, and second, there was an emphasis in Study
2403 on recruitment of patients in the lowest body weight
group. Moreover, mean and median parasite density tended
to be somewhat lower in patients who received the six-dose
regimen than in those on the four-dose regimen.
Parasitological cure rates. Cure rates (Table 5) with the
six-dose regimen were consistently higher than the four-dose
regimen in all analysis populations, with the difference being
greatest at 28 days. PCR-corrected day 28 cure rates were as
high as 96% for the six-dose regimen in the evaluable popu-
lation. In both the ITT and evaluable populations, the overall
difference between the two coartemether treatments in
terms of day 28 cure rates (with and without PCR correction)
was clinically and statistically significant (P < 0.0001).
If analyzed by body weight, the six-dose regimen was again
associated with consistently higher cure rates than the four-
dose regimen. Body weight had little if any effect on cure
rates with the six-dose regimen. PCR-corrected 28-day rates
(evaluable population) for the 5 to < 10, 10 to < 15, and 15–25
kg body weight ranges were 97.3%, 94.6%, and 97.1%, re-
spectively, for the six-dose regimen compared with 80.0% (10
to < 15 kg) and 72.1% (15–25 kg) for the four-dose regimen.
There were too few patients treated with the four-dose regi-
men in the 5- to < 10-kg body weight group to allow mean-
ingful cure rates to be calculated.
Times to parasite and fever clearance. Median PCT was
shorter with the six-dose (24.2 hours; 95% CI: 24.0, 35.8) than
the four-dose regimen (45.0 hours; 95% CI: 40.0, 48.0). The
proportion of patients with rapid parasite clearance (i.e.,
within 48 hours) was more than 80% for the two regimens
(six-dose: 94.2%; four-dose: 83.1%). Subanalyses according to
body weight yielded similar results (data not shown).
Analysis of FCT data suggested a more rapid resolution of
fever with the six-dose coartemether treatment regimen, al-
TABLE 4
Patient disposition and baseline characteristics (safety population)
Coartemether
4-dose regimen 6-dose regimen
Patients, n (%)
Enrolled 201 (100) 343 (100)
Discontinued 61 (30.3) 14 (4.1)
Sex, n (%)
Male 116 (57.7) 181 (52.8)
Female 85 (42.3) 162 (47.2)
Age (years)
Median 4.0 2.3
Range 1–12 0.2–12
Weight (kg)
Median 14.0 10.5
Range 8–25 5–25
Body temperature (°C)
Median 38.4 38.5
Range 35.9–40.7 36.7–40.9
Parasite density (L)
Median 36250 17051
Mean ± SD 41,006 ± 28,576 30,930 ± 31,700
Range 1,030–100,000 1,000–100,000
Four-dose regimen: studies 003, 008, 009, 010, 011, and 025.
Six-dose regimen: studies 025, 026, and 2403.
TABLE 5
Parasitological cure rates for coartemether by regimen
n/N (%) patients
4-dose regimen 6-dose regimen
ITT population (cure rate)
7-day 49/59 (83.1) 303/307 (98.7)†
14-day 113/162 (69.8) 300/307 (97.7)†
28-day* 88/153 (57.5) 295/343 (86.0)†
28-day*, PCR corrected 94/153 (61.4) 318/343 (92.7)†
Evaluable population (cure rate)
7-day 49/53 (92.5) 302/302 (100)‡
14-day 113/127 (89.0) 299/299 (100)†
28-day* 86/121 (71.1) 294/329 (89.4)†
28-day*, PCR corrected 92/121 (76.0) 317/329 (96.4)†
Four-dose regimen: studies 003, 008, 009, 010, 011, and 025.
Six-dose regimen: studies 025, 026, and 2403.
* For the four-dose regimen, only patients from studies 003, 009, and 025 were evaluated
because these studies provided both 28-day cure rates and related PCR-corrected data.
† P < 0.0001, ‡P < 0.001 (Fisher exact test, two-sided) compared to four-dose regimen.
n, number of patients cured; N, total number of patients.
TABLE 3
Number of patients on coartemether in each analysis population
Body weight range (kg)
4-dose regimen 6-dose regimen
5 to < 10 10 to < 15 15–25 Total 5 to < 10 10 to < 15 15–25 Total
Enrolled 8 101 92 201 155 114 74 343
ITT population for
7-day cure rate 0 57 2 59 154 108 45 307
14-day cure rate 8 96 58 162 154 108 45 307
28-day cure rate 0 70 83 153 155 114 74 343
Evaluable population for
7-day cure rate 0 51 2 53 152 106 44 302
14-day cure rate 6 76 45 127 151 105 43 299
28-day cure rate 0 60 61 121 149 111 69 329
Safety population 8 101 92 201 155 114 74 343
Four-dose regimen: studies 003, 008, 009, 010, 011, and 025.
Six-dose regimen: studies 025, 026, and 2403.
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though results could have been confounded by the extensive
use of antipyretic medications. For the six-dose regimen, me-
dian FCT was 7.9 hours (95% CI: 7.8, 7.9) and for the four-
dose regimen was 24.0 hours (95% CI: 23.8, 26.5). Again,
subanalyses according to body weight yielded similar results
(data not shown).
Gametocyte counts. The proportion of patients with game-
tocytes at early time-points (up to day 7) seemed to be lower
for the six-dose regimen than the four-dose regimen, suggest-
ing a rapid clearance of gametocytes, particularly with the
six-dose regimen, or clearance of merozoites before gameto-
cyte formation can occur (Table 6). Significantly fewer pa-
tients had circulating gametocytes at day 28 with the six-dose
than the four-dose regimen. Subanalyses according to body
weight were in line with the results obtained with the total
population (data not shown).
Adverse events. Only three (0.9%) and one (0.5%) patient
reported non-fatal SAEs in the six- and four-dose regimen,
respectively. Of the SAEs occurring in patients on the six-
dose regimen (convulsion, urticaria, viral hepatitis), only ur-
ticaria was suspected to be drug-related by the investigator.
This case was classified as an SAE because the patient was
hospitalized. The SAE reported in the four-dose group
(pneumonia) was not considered to be drug-related.
The majority of patients reported at least one AE after
baseline (Table 7). In both groups, most AEs were reported
during the first 3 days of treatment, which were generally mild
or moderate in severity. Severe AEs were infrequent (six-
dose: 5.2%; four-dose: 7.0%). The most frequent AEs ob-
served with both regimens included cough, anemia, anorexia,
vomiting, hepato-/splenomegaly, headache, and diarrhea,
most of which could have been disease related.20 The propor-
tion of patients with AEs was similar between the 5 to < 10,
10 to < 15, and 15–25 kg body weight groups, with incidence
rates of 75.5%, 72.8%, and 77.0%, respectively, for the six-
dose regimen, compared with 87.5%, 91.1%, and 91.3%, re-
spectively, for the four-dose regimen. There were some dif-
ferences between body weight groups in particular AEs, such
as headache or dizziness, which appeared less common in
very small infants. This may have been related to the limited
ability of these patients to communicate subjective symptoms
without outward sign. Moreover, because the AEs accounting
for the differences between body weight groups were gener-
ally of mild to moderate severity, those differences were not
considered to be clinically relevant.
There were some notable differences between regimens in
rates of individual AEs. Among the 14 most common AEs, 9
showed at least a 2-fold lower incidence with the six-dose than
the four-dose regimen (Table 7). With regard to AEs of spe-
cial interest, fewer patients in the six-dose than the four-dose
group showed AEs related to the central nervous system. Of
these, headache (six-dose: 9.9%; four-dose: 40.3%) and diz-
ziness (six-dose: 3.8%; four-dose: 16.4%) were by far the most
frequent ones. Other events included clonus in 3.8% of pa-
tients taking the six-dose regimen and 1.0% of those treated
with the four-dose regimen, hyperreflexia (six-dose: 1.7%;
four-dose: 0.5%), convulsions (six-dose: 0.3%; four-dose:
1.0%), and nystagmus, ataxia, and coordination abnormal, all
of which occurred in 1.0–1.5% of patients treated with the
four-dose regimen, but were not reported with the six-dose
regimen. Decreased hearing (hypoacusis) was reported in
3/201 (1.5%) of patients taking the four-dose regimen, but
was not reported in patients taking the six-dose regimen. All
cases of hypoacusis were of mild severity, and none were
considered to be drug-related.
AEs suspected to be drug-related are shown in Table 8.
Only a rather small proportion of patients who experienced
AEs had events that were suspected to be drug-related. Such
AEs were overall higher with the coartemether six-dose regi-
men than the four-dose regimen.
Clinical laboratory parameters. The pattern of changes
seen in clinical laboratory parameters was consistent with
acute malaria and its resolution, with no striking differences
between the four- and six-dose regimen of coartemether.
With both regimens, hemoglobin levels and hematocrit de-
creased from baseline to day 3 and subsequently increased. In
the six-dose group, a lower decrease to day 3 and a greater
increase to day 28 was observed than in the four-dose group.
Neither the six-dose regimen nor the four-dose regimen of
coartemether seemed to have any clinically relevant effect on
renal function, as assessed by serum creatinine levels. Paucity
of data prevented comparisons with regard to other labora-
tory parameters.
TABLE 6
Proportion of patients with gametocytes by time-point
(ITT population)
Patients (%)
Day
coartemether
4-dose regimen
(N 201)
6-dose regimen
(N 343)
0–3 19.4 9.9*
4–7 5.5 0.9*
8–14 0 0
15–28 3.0 0.3†
Four-dose regimen: studies 003, 008, 009, 010, 011, and 025.
Six-dose regimen: studies 025, 026, and 2403.
* P < 0.01, †P < 0.05 (Fisher exact test, two-sided) compared to four dose regimen.
N, total number of patients.
TABLE 7
Adverse events (after baseline but before recurrence of malaria) in
more than 10% of patients receiving coartemether, irrespective of
cause (safety population)
n (%) patients
Adverse event
coaretmether
4-dose regimen
(N  201)
6-dose regimen
(N  343)
Total 183 (91.0) 257 (74.9)
Cough 37 (18.4) 77 (22.4)
Anemia 49 (24.4) 77 (22.4)
Anorexia 80 (39.8) 63 (18.4)
Vomiting 59 (29.4) 60 (17.5)
Splenomegaly 51 (25.4) 43 (12.5)
Hepatomegaly 46 (22.9) 40 (11.7)
Headache 81 (40.3) 34 (9.9)
Diarrhea 27 (13.4) 33 (9.6)
Rigors 54 (26.9) 19 (5.5)
Nausea 34 (16.9) 16 (4.7)
Abdominal pain 52 (25.9) 16 (4.7)
Dizziness 33 (16.4) 13 (3.8)
Sleep disorder 33 (16.4) 8 (2.3)
Fatigue 62 (30.8) 3 (0.9)
Four-dose regimen: studies 003, 008, 009, 010, 011, and 025.
Six-dose regimen: studies 025, 026, and 2403.
Adverse events are listed according to decreasing frequency in the coartemether six-dose
group.
n, number of patients with adverse events; N, total number of patients.
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Electrocardiography. For both coartemether treatment
regimens, the incidence in QTc changes within specific ranges
were overall comparable for the six-dose and four-dose regi-
mens (Table 9). Specifically, the proportion of patients who
had clinically non-significant QTc changes of less than 30 ms
from baseline was greater for the six-dose than the four-dose
regimen. On the other hand, the four-dose regimen had
greater proportions of patients with QTc increases of 30–60 or
more than 60 ms than the six-dose regimen. This was gener-
ally consistent when QTc was calculated using either Bazett
or Fridericia formulae. Given the low number of patients with
ECG assessments in the four-dose group, differences between
treatment groups should be interpreted with caution.
DISCUSSION
The present pooled analysis was performed to confirm that
the six-dose regimen of coartemether is more efficacious
than the four-dose regimen in children while remaining
equally safe and well tolerated.
The main outcomes of this pooled analysis of individual
patient data from eight studies in children with acute, uncom-
plicated P. falciparum malaria, matched for demographic and
baseline disease characteristics and individual coartemether
doses, can be summarized as follows: 1) the parasitological
cure rate at 28 days is clinically and statistically significantly
higher with the six-dose than the four-dose regimen of coar-
temether; 2) the six-dose regimen is associated with a more
rapid clearance of parasites and fever and a faster and more
sustained reduction in gametocyte carriage; 3) patients in the
six-dose group show a markedly lower discontinuation rate
because of insufficient efficacy than patients on the four-dose
regimen; 4) the six-dose regimen is equally well tolerated as
the four-dose regimen in terms of AEs, SAEs, and laboratory
parameters; 5) ECG changes (in terms of QTc prolongations)
are infrequent and comparable between the two coarte-
mether dose regimens.
Efficacy. This analysis showed that the six-dose regimen of
coartemether is highly efficacious in the treatment of children
with a body weight as low as 5 kg, including those who are
likely to be non-immune. Analyses based on the ITT and
evaluable populations yielded PCR-corrected day 28 cure
rates of 93% and 96%, respectively. If compared with the
four-dose regimen, cure rates were significantly higher with
the six-dose regimen, irrespective of analysis population,
whereas the results in the ITT population might have been
slightly biased to the disadvantage of the four-dose regimen
because of a higher proportion of patients being lost to fol-
low-up, which were counted as treatment failures. Although
PCT and FCT were shorter with the six-dose regimen, the
proportion of patients with parasite clearance within 48 hours
was high for both coartemether regimens. Given the fact that
the two regimens are identical for the first 36 hours, this was
not surprising.
Our findings confirmed the results from Falade and oth-
ers14 who showed that the coartemether six-dose treatment of
children with falciparum malaria is highly efficacious in en-
demic countries of Africa, using a non-comparative study de-
sign. Moreover, results from our analysis corroborate findings
of a study in Thai adults that compared the six-dose and
four-dose regimens directly10 and of a recently performed
pooled analysis of data from adolescents and adults partici-
pating in randomized clinical trials (E. A. Mueller and others,
unpublished data).
With regard to reduction of gametocyte carriage, in this
analysis, the six-dose regimen acted faster and significantly
fewer patients showed circulating gametocytes at day 28 than
the four-dose regimen. Thus, the six-dose regimen may have
a favorable impact on malaria transmission. Decreasing the
transmission of any drug-resistant parasites that might have
been selected is of major public health interest.5,21
Tolerability and safety. The safety profile of the six-dose
regimen was not worse than that of the four-dose regimen. In
fact, the six-dose regimen was well tolerated in the treatment
of children down to 5-kg body weight. The observation of
lower AE rates with the six-dose regimen is most likely a
reflection of the fact that most of the observed AEs were
related to malaria symptoms, and the better efficacy associ-
ated with the six-dose regimen allowed a more rapid resolu-
tion of malaria and thus prevented worsening of symptoms
more effectively than the four-dose regimen. This is sup-
ported by the fact that most AEs were reported during the
TABLE 8
Adverse events (after baseline but before recurrence of malaria) in at
least 2% of patients receiving coartemether, suspected by the in-
vestigator to be drug-related (safety population)
n (%) patients
Adverse event
coartemether
4-dose regimen
(N  201)
6-dose regimen
(N  343)
Total 28 (13.9) 85 (24.8)
Anemia 3 (1.5) 15 (4.4)
Clonus 1 (0.5) 13 (3.8)
Vomiting 3 (1.5) 13 (3.8)
Eosinophilia 0 12 (3.5)
Diarrhea 2 (1.0) 11 (3.2)
Rash 1 (0.5) 9 (2.6)
Anorexia 8 (4.0) 4 (1.2)
Sleep disorder 4 (2.0) 1 (0.3)
Pyrexia 4 (2.0) 0
Rigors 4 (2.0) 0
Four-dose regimen: studies 003, 008, 009, 010, 011, and 025.
Six-dose regimen: studies 025, 026, and 2403.
Adverse events are listed according to decreasing frequency in the coartemether six-dose
group.
n, number of patients with adverse events; N, total number of patients.
TABLE 9
Summary of QTc increases from baseline* (safety population)
n (%) patients
coartemether
4-dose regimen 6-dose regimen
Bazett’s formula N  24 N  291
< 30 ms† 15 (62.5) 230 (79.0)
30–60 ms 8 (33.3) 49 (16.8)
> 60 ms 1 (4.2) 12 (4.1)
Fridericia’s formula N  17 N  291
< 30 ms† 7 (41.2) 193 (66.3)
30–60 ms 8 (47.1) 81 (27.8)
> 60 ms 2 (11.8) 17 (5.8)
Four-dose regimen: studies 003, 008, 009, 010, 011, and 025.
Six-dose regimen: studies 025, 026, and 2403.
* The highest increase recorded at any time during the study was used.
† Including decreases in QTc.
N, total number of patients with data; n, number of patients with at least one notable
value.
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first 3 days of treatment. Moreover, the six-dose regimen
group was composed of more very small children with a lim-
ited ability to communicate subjective symptoms.
Suspected drug-related AEs were overall more frequent
with the six-dose regimen of coartemether, which may look
surprising as a lower proportion of AEs of any cause was
observed with that regimen. However, this finding has to be
interpreted with caution because drug relationship, according
to the investigator’s judgment, might have been assessed dif-
ferently across studies. In addition, Study 2403, which pro-
vided most of the data on the six-dose regimen, followed an
open, non-comparative design, in which the investigators
knew they were prescribing a higher dose of coartemether
than would previously have been used in the patient popula-
tion represented in the study. This may have increased the
index of suspicion. In contrast, almost one third of the pa-
tients in the pooled population for the four-dose regimen
participated in double-blind comparative studies.
There has been some concern about the possible risk of
neurotoxicity with artemisinin derivatives in animals and
hearing decreases with coartemether in humans.22,23 In our
pooled analysis in children, the six-dose regimen was not as-
sociated with a worse neurologic safety profile than the four-
dose regimen. Headache and dizziness were by far the most
frequent neurologic AEs and were almost certainly symptoms
of malaria. Decreased hearing was not reported in patients
taking the six-dose regimen, thereby confirming results of a
recent study that indicated that coartemether has no influence
on auditory function.24
SAEs were infrequent, and only one (severe urticaria) re-
ported with the six-dose regimen was suspected to be drug-
related. One patient died of causes unrelated to study treat-
ment.
In terms of clinical laboratory parameters, the information
was limited, but findings were consistent with acute malaria
and its resolution after treatment, without major differences
between coartemether treatment regimens. In the six-dose
group, a lower decrease to day 3 in hemoglobin levels and
hematocrit and a greater increase to day 28 was observed than
in the four-dose group, most likely because of the better
therapeutic effect with the six-dose regimen.
Lumefantrine has some chemical similarities with halofan-
trine, a drug known to cause QTc interval prolongation. Con-
sequently, QTc values were evaluated in this pooled analysis.
Although the number of patients with ECG assessments in
the four-dose group was small, the six-dose regimen of coar-
temether did not seem to be associated with a greater fre-
quency of QTc prolongation than the low rate observed with
the four-dose regimen. Significant prolongation of the QTc
interval has been observed in young African children with
malaria (at day 4 versus baseline) in patients being treated
with coartemether, chloroquine, or sulfadoxine/pyri-
methamine (SP). The QTc prolongation seemed to be inde-
pendent of the treatment given but showed a weak correla-
tion to both baseline parasitemia and temperature.25 In view
of this, and the electrocardiographic safety of coartemether
shown before in healthy volunteers and malaria patients,26,27
it seems unlikely that the administration of the six-dose regi-
men of coartemether represents an increased cardiac risk in
the patient population studied.
Limitations. There was an imbalance between coarte-
mether treatment groups with regard to the proportion of
patients from double-blind studies compared with open-label
studies. This might have influenced the assessment of drug-
relationship of AEs. There were too few patients treated with
the four-dose regimen in the 5- to < 10-kg body weight group
to allow meaningful comparisons with the six-dose regimen
for that particular body weight range. Moreover, Study 2403
provided the vast majority of patients on the six-dose regi-
men. Hence, the patient sample providing data for that regi-
men might have been not fully representative of patients with
falciparum malaria from other geographical regions.
Conclusion. Based on this pooled analysis, the six-dose ad-
ministration schedule of coartemether is more efficacious
than the four-dose regimen in children with uncomplicated P.
falciparum malaria while remaining equally well tolerated.
The six-dose regimen is associated with high parasitological
cure rates even in non-immune infants of body weight as low
as 5 kg. This pooled analysis supports the harmonized use of
the six-dose regimen of coartemether in children as single
global dosing regimen.
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